Based on these findings supporting the radiosensitizing effect of lapatinib, RTOG1119 study which is a phase II randomized study for lapatinib combined with radiation therapy in patients with brain metastases from HER2-positive breast cancer is ongoing (NCT 01622868). This evidence concerns the gene ERBB2 and breast carcinoma.